Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)
This guidance re-emphasises the importance of discussing all ER-ve and HER2+ve breast cancer patients in the pre-operative MDT
National Institute for Health and Care Excellence (NICE), UK | United Kingdom
18.02.2016
Added: 18.02.2016
Classifications: Adjuvant & Neoadjuvant Treatment
Keywords: Neoadjuvant Chemotherapy/ NACT